Barclays keeps Guardant Health overweight, raises target to $220
Barclays maintained its overweight rating on Guardant Health and raised its price target to $220 from $200, according to Benzinga ratings coverage.
Story updates
02:44:21 PM UTC
SquawkNews
Guardant Health Price Target Raised to $220.00/Share From $200.00 by Barclays